Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Tag: Type 2 Diabetes


Clinical profiles and quality of care of subjects with type 2 diabetes according to their cardiovascular risk: an observational, retrospective study

March 8th 2021

A large proportion of subjects with T2D is at high or very high risk. Glucose-lowering drug therapies seem not to be adequately used with respect to their potential advantages in terms of cardiovascular risk reduction (Cardiovascular Diabetology)

Categories: Cardiovascular, News
Tags: Type 2 Diabetes

Categories: Cardiovascular
Tags: Type 2 Diabetes

Sex-specific differences in left ventricular mass and myocardial energetic efficiency in non-diabetic, pre-diabetic and newly diagnosed type 2 diabetic subjects

March 8th 2021

Left ventricle is subject to maladaptive changes with worsening of glucose tolerance, especially in women with newly diagnosed T2DM. The sex-specific increase in LVM and decrease in MEEi, both being predictors of CVD, may have a role in explaining the stronger impact of T2DM on the excess risk of CVD in women than in men (Cardiovascular Diabetology)

Categories: Cardiovascular, News
Tags: Type 2 Diabetes

Categories: Cardiovascular
Tags: Type 2 Diabetes

Sodium–Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies

March 6th 2021

In T2D, SGLT2is appear safe from the CV perspective and may have associated benefit in primary as well as secondary CVD prevention. For safety, they may be associated with an increased risk of GMI, LLA and DKA, although longer follow-up studies are needed (Diabetes Therapy)

Categories: Medication, News
Tags: SGLT2 inhibitors, Type 2 Diabetes

Categories: Medication
Tags: SGLT2 inhibitors, Type 2 Diabetes

Gut microbiota compositions and metabolic functions in type 2 diabetes differ with glycemic durability to metformin monotherapy

March 5th 2021

There were different compositions of gut microbiota with unique microbial metabolic pathways between type 2 diabetes with and without glycemic durability to metformin monotherapy. Microbial salvage by increasing thiamine biosynthesis might be beneficial for the metformin durable group to maintain optimal glycemic control (Diabetes Research and Clinical Practice)

Categories: News, Pathology
Tags: gut microbiota, metformin, Type 2 Diabetes

Categories: Pathology
Tags: gut microbiota, metformin, Type 2 Diabetes

Type 2 Diabetes and the Use of Real-Time Continuous Glucose Monitoring

March 4th 2021

Based on literature review, we summarized current data on the use of rtCGM in T2D management and provided future research direction to generate more evidence on the utility of CGM in this population (Diabetes Technology and Therapeutics)

Categories: Monitoring, News
Tags: rCGM, Type 2 Diabetes

Categories: Monitoring
Tags: rCGM, Type 2 Diabetes

Therapeutic inertia in the management of dyslipidaemia and hypertension in incident type 2 diabetes and the resulting risk factor burden: real‐world evidence from primary care

March 3rd 2021

Significant delay in initiating cardioprotective therapies was observed, time to first prescription was similar in primary prevention people irrespective of ASCVD risk status across all T2DM diagnosis age groups, resulting in poor risk factor control over 2‐years follow‐up (Diabetes, Obesity and Metabolism)

Categories: News, Treatment
Tags: dyslipidaemia, hypertension, Type 2 Diabetes

Categories: Treatment
Tags: dyslipidaemia, hypertension, Type 2 Diabetes

Severe Hypoglycemia Risk With Long-Acting Insulin Analogs vs Neutral Protamine Hagedorn Insulin

March 2nd 2021

In this cohort study, initiation of long-acting analogs was associated with a lower risk of ED visits or hospitalizations for hypoglycemia compared with NPH insulin in older patients with type 2 diabetes in Medicare. However, this association was not seen with concomitant prandial insulin use (JAMA)

Categories: Medication, News
Tags: hypoglycemia, insulin, Type 2 Diabetes

Categories: Medication
Tags: hypoglycemia, insulin, Type 2 Diabetes

Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study

March 2nd 2021

EMPA effectively reduced liver fat in mice and humans without changing epicardial, myocardial fat or myocardial energetics, rebutting the thrifty substrate hypothesis for cardiovascular protection of SGLT2 inhibitors (Cardiovascular Diabetology)

Categories: Medication, News
Tags: EMPACEF, Empagliflozin, Type 2 Diabetes

Categories: Medication
Tags: EMPACEF, Empagliflozin, Type 2 Diabetes

Results of a 24-Week Trial of Technosphere Insulin Versus Insulin Aspart in Type 2 Diabetes

February 25th 2021

Both TI and IA resulted in significant and clinically meaningful HbA1C reductions. TI also resulted in significant and clinically meaningful weight reductions. These data support the use of inhaled insulin as a treatment option for individuals with type 2 diabetes (Endocrine Practice)

Categories: Medication, News
Tags: insulin, Type 2 Diabetes

Categories: Medication
Tags: insulin, Type 2 Diabetes

Identifying patients at increased risk of hypoglycaemia in primary care: Development of a machine learning‐based screening tool

February 23rd 2021

Using demographic and medication data, a model for identifying patients at increased risk of hypoglycaemia was developed using machine learning. This model can be used as a tool in primary care to screen for patients with T2D who may need additional attention to prevent or reduce hypoglycaemic events (Diabetes/Metabolism Research and Reviews)

Categories: News, Screening
Tags: hypoglycemia, Type 2 Diabetes

Categories: Screening
Tags: hypoglycemia, Type 2 Diabetes

Changes in Cardiovascular Biomarkers Associated With the Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor Ertugliflozin in Patients With Chronic Kidney Disease and Type 2 Diabetes

February 20th 2021

The effects of ertugliflozin on natriuretic peptides and neurohormones are preserved in patients with moderate CKD and consistent with plasma volume reduction. The rise in HCT without a change in erythropoiesis supports the volume contraction mechanism of SGLT2 inhibitor therapy. These effects may be important physiologically and contribute to a lower risk of CVD with SGLT2 inhibitor treatment in people with type 2 diabetes (Diabetes Care)

Categories: Medication, News
Tags: SGLT2 inhibitors, Type 2 Diabetes

Categories: Medication
Tags: SGLT2 inhibitors, Type 2 Diabetes

Sodium–glucose cotransporter 2 inhibitor‐induced reduction in the mean arterial pressure improved renal composite outcomes in type 2 diabetes mellitus patients with chronic kidney disease: A propensity score‐matched model analysis in Japan

February 7th 2021

The degree of blood pressure reduction after SGLT2 inhibitor treatment influenced renal composite outcomes in Japanese type 2 diabetes mellitus patients with CKD, confirming the importance of blood pressure management in type 2 diabetes mellitus patients with CKD, even when they are under SGLT2 inhibitor treatment (Journal of Diabetes Investigation)

Categories: Medication, News
Tags: hypertension, SGLT2 inhibitors, Type 2 Diabetes

Categories: Medication
Tags: hypertension, SGLT2 inhibitors, Type 2 Diabetes

Use of Dipeptidyl Peptidase‐4 inhibitors and prognosis of COVID‐19 in hospitalized patients with type 2 diabetes: a propensity score analysis from the CORONADO study

February 3rd 2021

These data support the safety of DPP‐4 inhibitors for diabetes management during the COVID‐19 pandemic and they should not be discontinued (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: COVID ‐19, DPP4 inhibitors, Type 2 Diabetes

Categories: Medication
Tags: COVID ‐19, DPP4 inhibitors, Type 2 Diabetes

Characteristics and outcomes of pregnant women with type 1 or type 2 diabetes: a 5-year national population-based cohort study

January 29th 2021

Our data highlight persistent adverse pregnancy outcomes in women with type 1 or type 2 diabetes. Maternal glycaemia and BMI are the key modifiable risk factors. No maternity clinics were had appreciably better outcomes than any others, suggesting that health-care system changes are needed across all clinics (The Lancet Diabetes & Endocrinology)

Categories: Gestational, News
Tags: Type 1 Diabetes, Type 2 Diabetes

Categories: Gestational
Tags: Type 1 Diabetes, Type 2 Diabetes

Prediction of mortality and major cardiovascular complications in type 2 diabetes: External validation of UK Prospective Diabetes Study outcomes model version 2 in two European observational cohorts

January 27th 2021

The UKPDS‐OM2 consistently overpredicted the risk of mortality and MI in both cohorts during follow‐up. Period effects may partially explain the differences. Results indicate that transferability is not satisfactory for all outcomes, and new or adjusted risk equations may be needed before applying the model to the Italian or Dutch settings (Diabetes, Obesity and Metabolism)

Categories: Cardiovascular, Monitoring, News
Tags: Type 2 Diabetes

Categories: Cardiovascular, Monitoring
Tags: Type 2 Diabetes

Temporal Trends in Comorbidities and Cardiometabolic Risk Factors at the Time of Diagnosis of Type 2 Diabetes in UK

January 27th 2021

CMM and high ASCVD risk have been consistently increasing across all age groups and gender, particularly CMM in those <50 years. Our findings indicate that the ESC‐EASD recommendations need to change to consider the young‐onset people with T2DM as a high‐risk group as recommended in the Primary Care Diabetes Europe Position Statement (Diabetes, Obesity and Metabolism)

Categories: Cardiovascular, News
Tags: morbidity, Type 2 Diabetes

Categories: Cardiovascular
Tags: morbidity, Type 2 Diabetes

Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial

January 27th 2021

Metabolic surgery is more effective than conventional medical therapy in the long-term control of type 2 diabetes. Clinicians and policy makers should ensure that metabolic surgery is appropriately considered in the management of patients with obesity and type 2 diabetes (The Lancet)

Categories: Bariatric, News
Tags: Type 2 Diabetes

Categories: Bariatric
Tags: Type 2 Diabetes

Lack of awareness of liver organ damage in patients with type 2 diabetes

January 26th 2021

Despite increasing evidence of a frequent hepatic involvement associated with poor prognosis, awareness of suffering of advanced liver disease in patients with T2D is remarkably low, likely reflecting little recognition also among the team of health care professionals (Acta Diabetologica)

Categories: News, Pathology
Tags: liver, Type 2 Diabetes

Categories: Pathology
Tags: liver, Type 2 Diabetes

Effect of sodium–glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis

January 26th 2021

The use of SGLT2i was associated with significant improvements in cardiac diastolic function, plasma NT-proBNP level, and the KCCQ score in T2DM patients with or without chronic HF, but did not significantly affect cardiac structural parameters indexed by body surface area. The LVEF level was improved only in HF patients with reduced ejection fraction (Cardiovascular Diabetology)

Categories: Cardiovascular, Medication, News
Tags: SGLT2 inhibitors, Type 2 Diabetes

Categories: Cardiovascular, Medication
Tags: SGLT2 inhibitors, Type 2 Diabetes

What’s in a Name? Redefining Type 2 Diabetes Remission

January 25th 2021

This opinion piece explores existing definitions of diabetes remission and proposes a contemporary and comprehensive framework to help define this clinical state

Categories: Management, News
Tags: remission, Type 2 Diabetes

Categories: Management
Tags: remission, Type 2 Diabetes
  • 1
  • 2
  • 3
  • …
  • 50
  • Next Page »

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

Napp DiabetesNovo NordiskSanofi DiabetesAstraZeneca

Silver Sponsors

Abbott Diabetes CareAmgenWelsh Endocrinology and Diabetes Society (WEDS)About Ascensia Diabetes Care

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 Empagliflozin exenatide GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis lada liraglutide metformin microvascular mortality NAFLD NICE pioglitazone retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes USA Vitamin D

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2021 Glycosmedia Partnership